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match analysisMethods: Fifty-two patients with pathologically confirmed metastatic prostate cancer were
prospectively enrolled and treated with combined androgen blockade (goserelin and bicaluta-
mide) with zoledronic acid (4 mg every 4 weeks for 24 months). A propensity score-match with
logistic regression analysis was applied to select 50 pair-matched cohorts (both from ADT þ Z
and from historical control cohorts who had undergone ADT alone), and patient outcomes were
compared.
Results: Patients with ADT þ Z had significantly longer time to progression (TTP) than those
with ADT (median TTP; 24.2 vs. 14.0 months, p Z 0.0092), while no significant difference of
overall survival between two groups (pZ 0.1502). Multivariate analysis for biochemical recur-
rence revealed treatment with ADT was the sole independent prognostic factor (HR: 1.724,
95% CI: 1.06e2.86, p Z 0.0297).
Conclusion: Combination of zoledronic acid with ADT may prolong time to castration resistant
prostate cancer.
ª 2016 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Although androgen deprivation therapy (ADT) is still a
mainstay for the treatment of advanced or metastatic pros-
tate cancer, several serious adverse events has been re-
ported including skeletal-related events (SREs) due to
decreasing bone mineral density [1]. Zoledronic acid is a
potent bisphosphonate that selectively binds to bone min-
eral surfaces at sites of active bone remodeling, thereby
inhibiting osteoclastic bone resorption [2], and is recom-
mended for the prevention of skeletal morbidity in patients
with castration-resistant prostate cancer (CRPC) [3]. Pre-
clinical studies have also demonstrated anti-proliferative
activity against prostate cancer cells in vitro and in vivo
[4,5]. Combination of zoledronic acid therapy with ADT
(ADTþ Z) is likely to be beneficial not only for the prevention
of SREs, but also for anti-tumor effect in patients with hor-
mone-naı¨ve prostate cancer [6e9], while no definite onco-
logical benefit has been drawn due to the comparison with
historical control [6e8], or to subgroup analysis [9].
We conducted multi-institutional phase II study to
determine the benefits of ADT þ Z, and published the data
concerning the safety and efficacy preventing SREs [10].
This is a subgroup analysis of the selected cohort from the
original study with a primary endpoint of the SRE-free
survival at 24 months after treatment [10]. The aim of
this study is to study if ADT þ Z may have better oncological
outcomes than ADT alone with minimizing the potential bias
of the background using propensity score analysis [11].2. Materials and methods
2.1. Patient eligibility
Hormone-naı¨ve patients with pathologically confirmed
adenocarcinoma of the prostate and radiologic evidence of
bone metastasis were eligible. Detailed patient eligibility
and study design were reported elsewhere [10]. In brief, a
single-arm open-label multi-institutional phase II study was
conducted (clinical trials registry number: UMIN000007548).All patients provided written informed consent before
enrollment in the study. The primary endpoint was the 24-
month SRE-free survival rate. The secondary end points
were time to the first SRE, time to prostate-specific antigen
(PSA) progression, overall survival (OS), decrease in the
extent of bone disease, improvement in pain, and safety.
2.2. Treatment and evaluations
ADT consisted of bicalutamide 80 mg administered orally on
Day 1 and every day, goserelin acetate 10.8 mg administered
subcutaneously on Day 8 and every 12 weeks, and zoledronic
acid 4 mg administered intravenously on Day 8 and every 4
weeks. Eastern Cooperative Oncology Group performance
status (ECOG PS) of 0 or 1 were eligible, except for ECOG PS 2
due to bone pain was permitted. Biochemical recurrence
(BCR) was defined as the time to a proportional increase of
25% and an absolute increase of 2 ng/mL from the nadir,
confirmed by a second value obtained 3 weeks later. If no
decline from the baseline value was documented, time to
PSA progression was defined from 12weeks when therewas a
proportional increase of 25% and an absolute increase of
2 ng/mL from the baseline value [10]. Discontinuation of
bicalutamide was allowed if BCR was documented, or at the
discretion of the physician. Zoledronic acid was continued in
principle for 24months. Drug interruptions were required for
any drug-related toxicity of grade 3 or higher, and grade 2
toxicity with patients’ wish for withdrawal. Laboratory ex-
aminations (routine serum chemistry, hematology, and PSA
measurements) and assessments for SREs and adverse events
were performed at baseline and every 4 weeks thereafter.
Adverse events were graded using the National Cancer
Institute Common Terminology Criteria for Adverse Events,
version 3. The end points of the study were BCR and OS.
2.3. Statistical analysis
Baseline PSA at 3 months after initiation of ADT þ Z therapy
were dichotomized based on the receiver operating char-
acteristic (ROC) for BCR with statistical significant cutoff of
171 ng/mL (area under the curve (AUC): 0.6328,
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modeling techniques were used to estimate the association
of ADT þ Z with oncologic outcomes (BCR and OS) after
adjusting for potential treatment selection bias (age, bi-
opsy Gleason score, baseline PSA) using the propensity
score [11,12]. A KaplaneMeier’s plot with log-rank test was
used to estimate the statistical difference of time to all
cause death, or to BCR. A Cox proportional hazards model
was applied for the estimation of factors predicting disease
progression in multivariate analysis. All p values are 2-
sided. Statistical analysis was performed with SPSS
statistics version 21 (IBM, IL, USA), and JMP ver. 9 (SAS
Institute Inc., Cary, NC, USA).
3. Results
3.1. Assignment of the propensity score and
validation
The propensity score was assigned to 52 cases with ADT þ Z
and 134 historical control cohorts who had received ADT
alone (median PSA: 134 ng/mL, mean age: 73.9 years,
percent Gleason score  8: 61%), and ranked in order of the
score. Approximate values (within 0.03) were regarded as
score-match [12], and 50 pair-matched cases were selected
from each group. Potential prognostic factors affecting BCR
and OS (patient age, baseline PSA, and biopsy Gleason
score) were well balanced between ADT and ADT þ Z when
stratified by quintiles of propensity score. Calculated pro-
pensity score was validated as representative of each
covariate.
3.2. Overview of the study
Patient background between ADT and ADT þ Z was shown in
Table 1. Median age and baseline PSAwere 73.0 years (range,
55e86) and 241 ng/mL (range, 2.19e19201). Overall death
and BCR were 30 and 72 patients, respectively, with a median
follow-up of 33.2 months. Median time to PSA progressionTable 1 Patient background between ADT and ADT þ Z groups
All cases (n Z 100)
Propensity scorea 0.3
Age (year)b 73.0
PSA (ng/mL)b 241
Gleason score
6 6
7 28
8 66
Follow-up (month)b 33.2
TTP (month)b 15.0
Overall death (n) 30
Cause-specific (n) 25
Other cause (n) 5
Biochemical recurrence (n) 72
ADT, androgen deprivation therapy; PSA, prostate specific antigen; TTP
with zoledronic acid.
a Data presented as mean.
b Data presented as median.was 15.0 months. Overall death and BCR was significantly
more in ADT than in ADT þ Z (p Z 0.0156 and 0.0034,
respectively). Thirty-two of the 50 patients (64.0%) had
accomplished 24-month treatment of the zoledronic acid
with a median duration of 23.2 months ranging 1.8e43.8
months. Sixteen patients have been treated with the drug
due to patients’ wish. Reasons of the withdrawal of zole-
dronic acid were adverse event (4 cases), progressive disease
(7 cases), cancer death (3 cases), refusal by the patients (3
cases), and change to another hospital (1 case), respectively.
3.3. Comparison of patient outcomes between ADT
and ADT D Z
Patient outcomes were compared between two groups
(Fig. 1). Patients with ADT þ Z had significantly longer TTP
than those with ADT (Fig. 1(A), median TTP; 24.2 vs. 14.0
months, p Z 0.0092), whereas no significant difference of
OS between two groups (Fig. 1(B), p Z 0.1502). Multivar-
iate analysis revealed ADT þ Z was the sole independent
predictor for BCR with a 28% risk reduction of the event
(Table 2, HR: 1.724, 95%CI: 1.06e2.86, p Z 0.0297).
3.4. Subgroup analysis of patients with zoledronic
acid
Fig. 2 depicted subgroup analyses of 50 patients treated
with ADT þ Z stratified by Gleason score and baseline PSA.
Patients with lower Gleason score (7) had significantly
longer TTP in ADT þ Z than that in ADT (Fig. 2(A), median
TTP: not reached vs. 15.0 months, p Z 0.0157), while no
significant difference was shown in patients with higher
Gleason score (8) (Fig. 2(B), median TTP: 15.0 vs. 13.0
months, p Z 0.3243). Likewise, patients with lower PSA
(171 ng/mL) had significantly longer TTP in ADT þ Z than
that in ADT (Fig. 2(C), median TTP: not reached vs. 15.0
months, p Z 0.0207), whereas no significant difference in
those with higher PSA (>171 ng/mL) (Fig. 2(D), median TTP:
14.8 vs. 14.0 months, p Z 0.1636).adjusted by propensity score-match analysis.
ADT þ Z (n Z 50) ADT (n Z 50) p-Value
0.3 0.3 0.93
71.8 73.7 0.202
249 207 0.8722
0.5871
4 2
15 13
31 35
31.3 37.0 0.0363
24.2 14.0 0.0172
9 21 0.0156
7 18
2 3
29 43 0.0034
, time to PSA progression; ADT þ Z, androgen deprivation therapy
Figure 1 KaplaneMeier’s plot for (A) progression-free survival and (B) overall survival stratified by androgen deprivation therapy
with or without zoledronic acid. ADT, androgen deprivation therapy; ADT þ Z, androgen deprivation therapy with zoledronic acid;
PSA, prostate specific antigen.
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Adverse events in the ADT þ Z were observed in nine (18%),
including six cases of grade 3. The grade 3 osteonecrosis of
the jaw and renal dysfunction was reported in three (6%)
and one (2%) patients. No fetal adverse events was noted in
the combination group.
4. Discussion
Several literatures have suggested the anti-tumor effect of
zoledronic acid in patients with hormone-naı¨ve prostate
cancer [6e9]. Kamiya et al. [6] compared 23 cases with
zoledronic acid with ADT to 42 historical control cohorts
(ADT alone) regarding the PSA and bone turnover marker
declines, and concluded that combination of zoledronic
acid with ADT had better PSA and bone turnover marker
declines, suggesting the potential anti-tumor effect of
zoledronic acid. Okegawa et al. [7] reported that biopsy
Gleason score, pre-treatment serum N-telopeptide of type I
collagen (NTx), and treatment with zoledronic acid were
shown to be independent predictors of PSA failure-free
survival time. Uemura et al. [8] reported zoledronic acid
with ADT had significantly longer TTP and OS than ADTTable 2 Proportional hazard model for biochemical recurrence
Factor Univariate
HR 95%CI
Age 1.007 0.97e1.04
PSA 1 1.00e1.00
Treatment ADT vs. ADT þ Z 1.8275 1.13e2.99
Gleason score
6 Baseline
7 0.8506 0.28e3.66
8 1.549 0.57e6.38
ADT, androgen deprivation therapy; ADT þ Z, androgen deprivation talone (historical control) in patients with higher extent of
disease (grade 3). Ueno et al. [9] conducted randomized
controlled trial comparing the efficacy of progression-free
survival of zoledronic acid with ADT to ADT alone.
Although no significant difference was noted between two
groups, subgroup analysis demonstrated combination
treatment improved profression-free survival with 10-
month advance in median TTP for patients with high
Gleason score. In this study, we applied the propensity
score-match analysis which minimizes the selection bias
inherent in retrospective cohort studies by creating risk
quintiles to match subjects across treatment groups
[11e14]. Our results were in good agreement with previous
reports regarding the oncological benefit of BCR of zole-
dronic acid. Although BCR is a surrogate marker for cancer-
specific survival, duration of ADT, or time to CRPC was re-
ported to be well correlated with OS in patients with
metastatic prostate cancer [15]. Thus, it is worthwhile to
extend the median TTP by 10.2 months by adding zole-
dronic acid. The figure is identical to the data reported by
Ueno et al. [9] from patients with high Gleason score.
Subgroup analysis of our study, however, were in contrast
with the data that zoledronic acid was more effective in
higher Gleason score [9]. The discrepancy may result from
different patients’ backgrounds. Santini et al. [16] foundin patients with metastatic hormone naı¨ve prostate cancer.
Multivariate
p-Value HR 95%CI p-Value
0.6849 1 0.97e1.04 0.7755
0.0453 1 1.00e1.00 0.1305
0.0136 1.724 1.06e2.86 0.0297
0.0829 Baseline 0.2569
0.6826 0.22e2.99
1.09 0.38e4.60
herapy with zoledronic acid; PSA, prostate specific antigen.
Figure 2 KaplaneMeier’s plot for progression-free survival by androgen deprivation therapy with or without zoledronic acid in
patients who were sub-grouped with dichotomized Gleason score (A) (B), or PSA (C) (D). Gleason score was categorized Gleason
score 7 (A) and Gleason score 8 (B). PSA level was categorized PSA 171 ng/ml (C) and >171 ng/ml (D). PSA cut off (171 ng/mL)
was set based on the result of receiver operating characteristic. ADT, androgen deprivation therapy; ADT þ Z, androgen deprivation
therapy with zoledronic acid; PSA, prostate specific antigen.
Zoledronic acid with androgen-deprivation for prostate cancer 37repeated low-dose therapy with zoledronic acid (1 mg
every week for four times followed by 4 mg with a standard
28-day schedule) could induce an early significant and long-
lasting decrease of vascular endothelial epidermal growth
factor (VEGF) levels in 26 advanced solid tumor patients.
The report may support our hypothesis of direct anti-tumor
effect of zoledronic acid. On the other hand, care must be
taken for adverse events including osteonecrosis of the jaw
or renal dysfunction as found in our study. Baseline status
of oral hygiene and potential chronic kidney disease (CKD)
should be checked before starting zoledronic acid.
There are several limitations of the study. Retrospective
study with relatively small number of cohort, inter-
pathologist variation of Gleason score from multiple in-
stitutions should be considered for the correct interpreta-
tion of the study. These factors are likely to yield
discrepancy between our result and other literatures
regarding the efficacy of subgroup analysis. It should be
noted that the application of propensity-match score
analysis is not always a standard one for the prospectively
collected cohort because propensity analysis was originally
developed for the observation study which was difficult for
randomization. Since there are several studies in which
authors applied propensity analysis in a similar way,
application of this analysis might be acceptable [17,18].5. Conclusion
Combination therapy of 2-year zoledronic acid treatment
with ADT may have better efficacy than ADT alone, and
prolong time to castration resistant prostate cancer with a
median of 10.2 months in patients who have lower baseline
PSA or less than 8 Gleason score.Conflicts of interest
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